Please login to the form below
Takhzyro
This page shows the latest Takhzyro news and features for those working in and with pharma, biotech and healthcare.
Latest news
-
Takeda’s HAE drug Takhzyro backed by NICE
Like Firazyr and Cinryze, Takhzyro was originally developed by Shire, which has been absorbed by Takeda in a $63bn takeover. ... Analysts have predicted that Takhzyro could make up to $2bn in peak sales.
-
EMA sees approval numbers rise in 2018
These were Roche’s Hemlibra, Shire’s Takhzyro, Alnylam’s Onpattro and Tegsedi. US shutdown and Brexit.
-
Shire bags US approval for constipation drug Motegrity
therapy Cinryze, and has also just had a positive verdict for Takhzyro (lanadelumab) for HAE from the FDA.
-
Shire’s angioedema drug Takhzyro claims EU approval
The company maintains that Takhzyro has the potential to expand the HAE prevention market, particularly in international markets, as it is easier to administer than other drugs. ... Analysts at Bernstein recently predicted that Takhzyro will eventually
-
Shire’s angioedema drug Takhzyro recommended in Europe
The European Medicines Agency's CHMP committee has recommended Shire’s Takhzyro (lanadelumab), a new rare disease treatment which has blockbuster potential. ... However Takhzyro has an advantage in its dosing regimen - patients need only take it once
More from news
Approximately 4 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
The first test of this will be Shire’s new blockbuster-in-waiting Takhzyro, which gained EMA approval in November, for the rare disease hereditary angioedema (HAE). ... Analysts at Bernstein recently predicted that Takhzyro will eventually dominate the
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- The patient voice – the value of patient-reported outcomes in HTA
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
- ONS data reveals significant decrease in COVID-19 antibodies
- Researchers create ‘world’s largest’ database for predicting cancer treatment response
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- ONS data reveals significant decrease in COVID-19 antibodies
- Sanofi and Innovent Biologics to develop oncology drugs for patients in China
PMHub
Medscape Education Global
Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
